login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
REZOLUTE INC (RZLT) Stock News
USA
- NASDAQ:RZLT -
US76200L3096
-
Common Stock
9.65
USD
-0.51 (-5.02%)
Last: 11/20/2025, 4:04:00 PM
9.65
USD
0 (0%)
After Hours:
11/20/2025, 4:04:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
RZLT Latest News, Press Relases and Analysis
All
Press Releases
8 days ago - By: Zacks Investment Research
All You Need to Know About Rezolute (RZLT) Rating Upgrade to Buy
8 days ago - By: Zacks Investment Research
Can Rezolute (RZLT) Climb 49.4% to Reach the Level Wall Street Analysts Expect?
10 days ago - By: Rezolute, Inc.
Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10 days ago - By: Rezolute, Inc.
Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
14 days ago - By: Rezolute, Inc.
Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update
15 days ago - By: Rezolute, Inc.
Rezolute to Host Virtual Investor Event on Ersodetug Development Program
15 days ago - By: Rezolute, Inc.
Rezolute to Host Virtual Investor Event on Ersodetug Development Program
a month ago - By: Rezolute, Inc.
Rezolute to Participate in Upcoming Investor Conferences
a month ago - By: Rezolute, Inc.
Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
a month ago - By: Rezolute, Inc.
Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2 months ago - By: Benzinga
- Mentions:
ABT
BSX
LLY
PFE
...
10 Health Care Stocks Whale Activity In Today's Session
2 months ago - By: Rezolute, Inc.
Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
2 months ago - By: Rezolute, Inc.
Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
3 months ago - By: Rezolute, Inc.
Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism
3 months ago - By: Rezolute, Inc.
Rezolute to Participate in Upcoming Investor Conferences
3 months ago - By: Rezolute, Inc.
Rezolute to Participate in Upcoming Investor Conferences
3 months ago - By: Rezolute, Inc.
Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer
3 months ago - By: Rezolute, Inc.
Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer
3 months ago - By: Benzinga
- Mentions:
CLDX
BMY
HUM
TEM
...
10 Health Care Stocks Whale Activity In Today's Session
4 months ago - By: Rezolute, Inc.
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
4 months ago - By: Rezolute, Inc.
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
4 months ago - By: Rezolute, Inc.
Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)
4 months ago - By: Rezolute, Inc.
Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)
6 months ago - By: Rezolute, Inc.
Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism
6 months ago - By: Yahoo Finance
- Mentions:
DHI
CMG
F
Rezolute, Inc. (RZLT): Analysts See 260% Upside Potential
6 months ago - By: Yahoo Finance
- Mentions:
SPTN
HD
HLIT
IDCC
...
Number Sense: Will retail define SpartanNash’s future?
6 months ago - By: Rezolute, Inc.
Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
6 months ago - By: Rezolute, Inc.
Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
7 months ago - By: Rezolute, Inc.
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
7 months ago - By: Rezolute, Inc.
Rezolute to Participate in Upcoming Investor Conferences
7 months ago - By: Rezolute, Inc.
Rezolute to Participate in Upcoming Investor Conferences
7 months ago - By: Rezolute, Inc.
Rezolute, Inc. Announces Closing of Underwritten Offering
7 months ago - By: Rezolute, Inc.
Rezolute, Inc. Announces Closing of Underwritten Offering
7 months ago - By: Rezolute, Inc.
Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants
Please enable JavaScript to continue using this application.